Skip to main content

Promotion of plasticity as a treatment for neurodegenerative conditions

Objective

Neurodegenerative diseases all cause damage to the circuitry of the nervous system, with loss of connections, axons and neurons. The loss can be gradual, as in Alzheimer’s disease, rapid as in stroke, or intermediate as in the delayed neuronal loss after stroke. Following damage, the nervous system is able partially to compensate through the formation of alternative connections and pathways, a process known as plasticity. Adults are therefore able to regain considerable function after stroke, and to compensate for the synapse and cell loss of Alzheimer’s disease until it reaches a critical level. Children undergo a period of enhanced plasticity in most parts of the CNS at the end of development, known as critical periods. During these periods their ability to compensate for damage to the CNS is in many cases much greater than in adults. The overall concept behind this application is that restoration of the function in neurodegeneration can be achieved through plasticity (the formation of new functional connections, withdrawal of inappropriate connections, modulation of synaptic strength). Promoting increased plasticity in selected parts of the adult nervous system back to the level seen in children is a powerful method of enhancing recovery of function in animal models. Plasticity-promoting treatments could therefore be beneficial in a wide range of conditions that damage the CNS. The PLASTICISE project integrates scientists from four scientific areas 1) Development of methods to promote plasticity 2) Development of models of neurodegenerative disease 3) Imaging of plasticity at the macro and micro level 4) Study of recovery of function through plasticity in human patients with brain disorders. The concept that unites the partners is the belief that treatments that enhance plasticity will become one of key medications that will improve neurological function in the damaged human nervous system. The purpose of the project is to bring this moment closer.

Field of science

  • /medical and health sciences/basic medicine/neurology/stroke
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/basic medicine/neurology/alzheimer

Call for proposal

FP7-HEALTH-2007-B
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 871 931,92
Administrative Contact
Renata Schaeffer (Ms.)

Participants (15)

UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 694 760
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Anita Buchli (Dr.)
CONSIGLIO NAZIONALE DELLE RICERCHE
Italy
EU contribution
€ 338 360
Address
Piazzale Aldo Moro 7
00185 Roma
Activity type
Research Organisations
Administrative Contact
Maria Grazia Piga (Ms.)
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
Netherlands
EU contribution
€ 301 130
Address
Kloveniersburgwal 29 Het Trippenhuis
1011 JV Amsterdam
Activity type
Other
Administrative Contact
Cor Van Leeuwen (Mr.)
Novartis Forschungsstiftung
Switzerland
EU contribution
€ 338 930
Address
Maulbeerstrasse 66
4058 Basel
Activity type
Research Organisations
Administrative Contact
Dorothy Searles (Ms.)
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Switzerland
EU contribution
€ 338 930
Address
Batiment Ce 3316 Station 1
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Patrick Aebischer (Prof.)
University College London
United Kingdom
EU contribution
€ 641 060
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kent Lee (Mr.)
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 338 930
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Anthony Holtmaat (Prof.)
UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 351 280
Address
Hugstetter Strasse 49
79106 Freiburg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerhard Henninger (Mr.)
INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK
Poland
EU contribution
€ 330 338
Address
Ul. Ludwika Pasteura 3
02 093 Warszawa
Activity type
Research Organisations
Administrative Contact
Marta Rucinska (Ms.)
Klinik Max Planck Institut für Psychiatrie
Germany
EU contribution
€ 351 440
Address
Hofgartenstrasse 8
80539 Muenchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patrice Wegener (Mr.)
PHARMAXON SAS

Participation ended

France
EU contribution
€ 53 655,08
Address
Parc Scientifique De Luminy
13288 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jean-Chrétien Norreel (Dr.)
D-Pharm LTD
Israel
EU contribution
€ 14 400
Address
Sapir Street 7
76123 Rehovot
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tami Horovitz (Dr.)
DANDO WEISS & COLUCCI LIMITED
United Kingdom
EU contribution
€ 229 500
Address
Lower Bristol Road Minerva House
BA2 9ER Bath
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jonathan Dando (Dr.)
NOVARTIS PHARMA AG
Switzerland
EU contribution
€ 2 400
Address
Lichtstrasse 35
4056 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Melissa Cooper Shinske (Ms.)
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
United Kingdom
EU contribution
€ 2 400
Address
Great West Road 980
TW89GS Brentford
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stephen Sheldon (Mr.)